Compare IRDM & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRDM | CRSP |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | Switzerland |
| Employees | 975 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.9B |
| IPO Year | 2007 | 2016 |
| Metric | IRDM | CRSP |
|---|---|---|
| Price | $42.35 | $48.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 17 |
| Target Price | $29.80 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 12.77 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $871,659,000.00 | $289,590,000.00 |
| Revenue This Year | $3.18 | $807.72 |
| Revenue Next Year | $2.50 | $172.52 |
| P/E Ratio | $218.15 | ★ N/A |
| Revenue Growth | 4.93 | ★ 9169.85 |
| 52 Week Low | $15.65 | $35.38 |
| 52 Week High | $44.61 | $78.48 |
| Indicator | IRDM | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.30 | 39.82 |
| Support Level | $17.20 | $44.82 |
| Resistance Level | $44.36 | $60.45 |
| Average True Range (ATR) | 2.01 | 2.58 |
| MACD | -0.11 | -0.49 |
| Stochastic Oscillator | 69.45 | 0.58 |
Iridium Communications Inc is the commercial provider of communications services offering true globalised coverage, connecting people, organizations, and assets to and from anywhere, in real time. The company is a provider of mobile voice and data communications services through a constellation of low-earth-orbiting satellites. Iridium's solutions are ideally suited for industries such as maritime, aviation, government/military, emergency/humanitarian services, mining, forestry, oil and gas, heavy equipment, transportation, and utilities. Iridium also provides service to subscribers from the U.S. Department of Defense, as well as other civil and government agencies world-wide. The Company operates in one business segment, providing satellite communications services and products.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.